Bladder Cancer Care

As part of their continued bladder cancer care programme, medac Pharma has developed the first closed instillation system supplied as standard with Mitomycin medac and BCG-medac, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Mitomycin medac and BCG-medac are both licensed for intravesical use.

Educational information

Visit our Educational information page with videos on best practice for managing NMIBC and bladder cancer care, as well more information on medac Academy, an education platform for Healthcare Professionals with CPD certified eLearning and other educational content.